These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27531814)

  • 1. [PI3K/AKT/mTOR Pathway and Pediatric T Acute Lymphoblastic Leukemia-Review].
    Shi LX; Wang JH; Shi XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1269-74. PubMed ID: 27531814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.
    Martelli AM; Lonetti A; Buontempo F; Ricci F; Tazzari PL; Evangelisti C; Bressanin D; Cappellini A; Orsini E; Chiarini F
    Adv Biol Regul; 2014 Sep; 56():6-21. PubMed ID: 24819383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
    Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
    J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
    Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
    Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
    Alameen AA; Simioni C; Martelli AM; Zauli G; Ultimo S; McCubrey JA; Gonelli A; Marisi G; Ulivi P; Capitani S; Neri LM
    Oncotarget; 2016 Aug; 7(34):55690-55703. PubMed ID: 27494886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.
    Simioni C; Martelli AM; Zauli G; Vitale M; McCubrey JA; Capitani S; Neri LM
    J Cell Physiol; 2018 Oct; 233(10):6440-6454. PubMed ID: 29667769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells.
    Silva A; Gírio A; Cebola I; Santos CI; Antunes F; Barata JT
    Leukemia; 2011 Jun; 25(6):960-7. PubMed ID: 21455214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.
    Wang Y; Chen B; Wang Z; Zhang W; Hao K; Chen Y; Li K; Wang T; Xie Y; Huang Z; Tong X
    Oncotarget; 2016 Dec; 7(50):82851-82863. PubMed ID: 27756877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy.
    Martelli AM; Tabellini G; Ricci F; Evangelisti C; Chiarini F; Bortul R; McCubrey JA; Manzoli FA
    Adv Biol Regul; 2012 Jan; 52(1):214-27. PubMed ID: 21983557
    [No Abstract]   [Full Text] [Related]  

  • 12. [Recent studies on PI3K/AKT/mTOR signaling pathway in hematopoietic stem cells].
    Zhang YC; Cheng T; Yuan WP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):245-9. PubMed ID: 23484729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL).
    Ehm P; Grottke A; Bettin B; Jücker M
    Cell Signal; 2022 May; 93():110301. PubMed ID: 35259456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Reaserch Advances on the Role of PI3K/AKT Signaling Pathway and MiRNA in Acute T-Cell Lymphocytic Leukemia--Review].
    Li YJ; Li XF; Yang EH; Shi M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1344-1347. PubMed ID: 31418405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-κB activity in B cell precursor-acute lymphoblastic leukemia.
    Toosi B; Zaker F; Alikarami F; Kazemi A; Teremmahi Ardestanii M
    Biomed Pharmacother; 2018 Jun; 102():428-437. PubMed ID: 29574283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
    Canté-Barrett K; Spijkers-Hagelstein JA; Buijs-Gladdines JG; Uitdehaag JC; Smits WK; van der Zwet J; Buijsman RC; Zaman GJ; Pieters R; Meijerink JP
    Leukemia; 2016 Sep; 30(9):1832-43. PubMed ID: 27174491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.
    Fuka G; Kantner HP; Grausenburger R; Inthal A; Bauer E; Krapf G; Kaindl U; Kauer M; Dworzak MN; Stoiber D; Haas OA; Panzer-Grümayer R
    Leukemia; 2012 May; 26(5):927-33. PubMed ID: 22094587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the mTOR Pathway in Leukemia.
    Dinner S; Platanias LC
    J Cell Biochem; 2016 Aug; 117(8):1745-52. PubMed ID: 27018341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of FAPP2 gene induces cell autophagy and inhibits PI3K/AKT/mTOR pathway in T-cell acute lymphoblastic leukemia.
    Yuan T; Wang J; Shi C; Wang Y; Xia B; Xu W; Yang H; Yang Y; Ye MT; Khalid S; Liang Y; Tian C; You MJ; Wang Y
    Hematol Oncol; 2022 Apr; 40(2):249-257. PubMed ID: 34796518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).
    Evangelisti C; Evangelisti C; Chiarini F; Lonetti A; Buontempo F; Bressanin D; Cappellini A; Orsini E; McCubrey JA; Martelli AM
    Int J Oncol; 2014 Sep; 45(3):909-18. PubMed ID: 24968804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.